Zobrazeno 51 - 60
of 551
pro vyhledávání: '"BUZDAR, A"'
Publikováno v:
Current Problems in Surgery. 45:13-55
Autor:
Aman U. Buzdar, William Fraser Symmans, Thomas A. Buchholz, Lajos Pusztai, Gabriel N. Hortobagyi, S. W. Kau, Henry Mark Kuerer, Karen O. Anderson, A. M. Gonzalez-Angulo, Kenneth R. Hess, Debra Frye, Fabrice Andre, Chafika Mazouni
Publikováno v:
Annals of Oncology. 18:874-880
Background: We examined if inclusion of a taxane and more prolonged preoperative chemotherapy improves pathologic complete response (pCR) rate in estrogen receptor (ER)-positive breast cancer compared with three to four courses of 5-fluorouracil, dox
Autor:
Francisco J. Esteva, Lajos Pusztai, Kristine Broglio, Chafika Mazouni, Angeline Hall, Herbert A. Fritsche, Massimo Cristofanilli, Gabriel N. Hortobagyi, Aman U. Buzdar, Fabrice Andre
Publikováno v:
Cancer. 109:496-501
BACKGROUND. The purpose of the study was to determine the utility of quantitation of the extracellular domain (ECD) of the HER-2/neu receptor in the serum for predicting response to treatment in patients with primary breast cancer receiving neoadjuva
Autor:
Shu Wan Kau, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo, Aman U. Buzdar, Kristine Broglio, Shaheenah Dawood, Florentia Peintinger, Rabiul Islam, William Fraser Symmans
Publikováno v:
Cancer. 110:1195-1200
BACKGROUND. A previously published prospective randomized phase 3 trial showed that administration of 24 weeks of primary systemic chemotherapy (PST) with paclitaxel and FEC75 (fluorouracil, epirubicin, cyclophosphamide) concurrently with trastuzumab
Autor:
Aman U. Buzdar
Publikováno v:
Cancer. 110:2394-2407
Despite proven benefits of neoadjuvant chemotherapy in patients with locally advanced, invasive breast cancer, no regimen is recommended as the treatment of choice. Neoadjuvant chemotherapy regimens encompass single-agent and combination therapy and
Autor:
Francisco J. Esteva, Gabriel N. Hortobagyi, Aman U. Buzdar, Lajos Pusztai, Marjorie C. Green, Vicente Valero, Sonja E. Singletary, Kelly K. Hunt, Michael S. Ewer, Richard L. Theriault, Nuhad K. Ibrahim, William Fraser Symmans, Kristine Broglio, Thomas A. Buchholz, Deborah Francis, Aysegul Sahin
Publikováno v:
Clinical Cancer Research. 13:228-233
Purpose: Findings from our previously published phase III randomized trial showed a high pathologic complete remission (CR) rate in patients with human epidermal growth factor receptor 2–positive breast cancer after the concurrent administration of
Autor:
Pierre Fumoleau, Ian E. Smith, Kathleen I. Pritchard, William J. Gradishar, Bent Ejlertsen, Deborah Lindquist, Nora Horick, Kathrin Strasser-Weippl, Miguel Martin, Paul E. Goss, E. Rappold, Aman U. Buzdar, Dianne M. Finkelstein, Martine Piccart-Gebhart, Joyce O'Shaughnessy, Frances M. Boyle, Beverly Moy
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Breast Cancer Research : BCR
Breast cancer research, 17 (1
Consejería de Sanidad de la Comunidad de Madrid
Breast Cancer Research : BCR
Breast cancer research, 17 (1
Introduction: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30cb164390a4db7e64d5a4698d8161ee
https://hdl.handle.net/20.500.12530/22155
https://hdl.handle.net/20.500.12530/22155
Autor:
V. Bossuyt, E. Provenzano, W.F. Symmans, J.C. Boughey, C. Coles, G. Curigliano, J.M. Dixon, L.J. Esserman, G. Fastner, T. Kuehn, F. Peintinger, G. von Minckwitz, J. White, W. Yang, S. Badve, C. Denkert, G. MacGrogan, F. Penault-Llorca, G. Viale, D. Cameron, Helena Earl, Emilio Alba, Ana Lluch, Joan Albanell, Keith Amos, Wojciech Biernat, Hervé Bonnefoi, Aman Buzdar, Paul Cane, Sarah Pinder, Lesley Carson, Diana Dickson-Witmer, Gyungyub Gong, Jimmy Green, Chih-Yi Hsu, Ling-Ming Tseng, Judith Kroep, A. Marilyn Leitch, Venetia Sarode, Eleftherios Mamounas, Paul Kelly Marcom, Paolo Nuciforo, Soonmyung Paik, Vicente Peg, David Peston, Jean-Yves Pierga, Miguel Quintela-Fandino, Roberto Salgado, William Sikov, Jeremy Thomas, Gary Unzeitig, Jelle Wesseling
Publikováno v:
Annals of Oncology, 26(7), 1280-91
Bossuyt, V, Provenzano, E, Symmans, W F, Boughey, J C, Coles, C, Curigliano, G, Dixon, J M, Esserman, L J, Fastner, G, Kuehn, T, Peintinger, F, Von Minckwitz, G, White, J, Yang, W, Badve, S, Denkert, C, Macgrogan, G, Penault-llorca, F, Viale, G & Cameron, D 2015, ' Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration ', Annals of Oncology, vol. 26, pp. 1280-1291 . https://doi.org/10.1093/annonc/mdv161
Annals of oncology : official journal of the European Society for Medical Oncology, vol 26, iss 7
Bossuyt, V, Provenzano, E, Symmans, W F, Boughey, J C, Coles, C, Curigliano, G, Dixon, J M, Esserman, L J, Fastner, G, Kuehn, T, Peintinger, F, Von Minckwitz, G, White, J, Yang, W, Badve, S, Denkert, C, Macgrogan, G, Penault-llorca, F, Viale, G & Cameron, D 2015, ' Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration ', Annals of Oncology, vol. 26, pp. 1280-1291 . https://doi.org/10.1093/annonc/mdv161
Annals of oncology : official journal of the European Society for Medical Oncology, vol 26, iss 7
Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd7b2096c68de93c521428ca2e8df1de
https://hdl.handle.net/1887/97151
https://hdl.handle.net/1887/97151
Autor:
Florentia Peintinger, Aman U. Buzdar, Funda Meric-Bernstam, Henry Mark Kuerer, Marjorie C. Green, Judy C. Boughey, Keith Anderson, Gary J. Whitman, S. Eva Singletary, Tanya W. Stephens, W. Fraser Symmans, Kelly K. Hunt
Publikováno v:
Annals of Surgical Oncology. 13:1443-1449
Residual tumor size after neoadjuvant chemotherapy is an important consideration in surgical planning. We examined the accuracy of the combination of mammography and sonography in predicting pathologic residual tumor size. Tumor size was evaluated by
Autor:
Henry L. Gomez, Daniel J. Booser, Vicente Valero, Keith Anderson, Lajos Pusztai, Richard L. Theriault, Peter J. Dempsey, Aman U. Buzdar, Roman Rouzier, Nuhad K. Ibrahim, Gabriel N. Hortobagyi, Tatiana Vidaurre, Jeffrey S. Ross, Nour Sneige, Kenneth R. Hess, Jaime A. Mejia, W. Fraser Symmans
Publikováno v:
Journal of Clinical Oncology. 24:4236-4244
Purpose We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases. Patients